ARFIP1

Arfaptin-1 (ARFIP1) is a cytosolic BAR-domain protein that functions at the trans-Golgi network as a GTPase-effector regulator of membrane deformation and carrier scission in the secretory and retrograde transport pathways (PMID:9038142, PMID:21239483). It was first defined as a selective effector of GTP-bound class I ARFs, binding preferentially to the activated, GTP-loaded forms of ARF1/ARF3 (and ARF5/ARF6) independent of myristoylation and translocating from cytosol to Golgi membranes in a GTPγS-dependent, brefeldin A-sensitive manner (PMID:9038142, PMID:16413282). Through this interaction it acts as a negative regulator of ARF function, inhibiting ARF-stimulated phospholipase D and cholera toxin ADP-ribosyltransferase activities in a manner requiring the ARF N-terminus, and dampening ARF/PLD-dependent secretory output in cells (PMID:9694811, PMID:9989604, PMID:12606037). At the TGN its BAR domain additionally binds Arl1—competing with golgins for this site—and incorporates arfaptin-1 into nascent vesicular and tubular carriers, where it negatively regulates Arl1-dependent retrograde endosome-to-Golgi transport and contributes to clathrin/AP-1 carrier scission downstream of phosphoinositide conversion and actin-based tubulation (PMID:21239483, PMID:25789876, PMID:28854360). Arfaptin-1 operates as a scission checkpoint: protein kinase D phosphorylates it at serine 132 to relieve its inhibition of ARF activity, and loss of this regulation produces secretory granule scission defects and abolishes glucose-stimulated insulin secretion in pancreatic β cells (PMID:22981988).

1. 1997 High

   Established arfaptin-1 as a bona fide ARF effector by showing it is a cytosolic protein that selectively recognizes the activated state of class I ARFs and is recruited to the Golgi accordingly.

   Evidence Yeast two-hybrid, recombinant binding assays, subcellular fractionation, and COS-cell immunofluorescence

   PMID:9038142

   Open questions at the time

   • Did not define the functional consequence of ARF binding
   • BAR-domain structural basis of membrane recruitment not addressed
2. 1998 High

   Defined arfaptin-1 as a negative regulator of ARF enzymatic output, showing it inhibits ARF-stimulated PLD and ADP-ribosyltransferase without altering ARF nucleotide cycling.

   Evidence In vitro enzymatic assays with recombinant proteins and ARF deletion/mutant analysis

   PMID:9694811

   Open questions at the time

   • Cellular relevance of in vitro inhibition not yet established
   • Mechanism by which the ARF N-terminus mediates inhibition unresolved
3. 1999 Medium

   Connected arfaptin-1's ARF/PLD inhibition to cellular transport and secretion, and mapped the arfaptin-1 regions required for ARF binding and inhibition.

   Evidence Overexpression in NIH 3T3 and HT1080 cells with PLD, VSV-G glycosylation, and MMP-9 secretion readouts; membrane fractionation with deletion mutants

   PMID:10413101 PMID:9989604

   Open questions at the time

   • Effects rely on overexpression in single labs
   • Whether endogenous arfaptin-1 sets the same set-point not tested
4. 2005 Medium

   Refined effector specificity, confirming arfaptin-1 binds only GTP-loaded ARFs and not Rac1, distinguishing it from the GDP-Rac-binding paralog arfaptin-2.

   Evidence In vitro binding assays with nucleotide-loaded Arf and Rac1 isoforms

   PMID:16413282

   Open questions at the time

   • Methods-chapter data from a single lab
   • Functional consequence of isoform-specific binding not addressed
5. 2011 High

   Identified a distinct BAR-domain-dependent Arl1 interaction and direct role in membrane deformation, repositioning arfaptin-1 as a carrier-shaping factor at the TGN rather than purely an ARF inhibitor.

   Evidence Co-IP, BAR-domain deletion mutants, siRNA knockdown, and time-lapse imaging of Golgi carriers

   PMID:21239483

   Open questions at the time

   • How ARF binding and Arl1 binding are coordinated unclear
   • Cargo carried by arfaptin-positive carriers not defined
6. 2012 High

   Revealed the regulatory switch controlling arfaptin-1 activity, showing PKD phosphorylation at Ser132 relieves ARF inhibition to permit secretory granule scission, with physiological consequences for insulin secretion.

   Evidence In vitro kinase assay, phospho-mutant analysis, RNAi, insulin secretion assay, and EM of β cells

   PMID:22981988

   Open questions at the time

   • Structural effect of Ser132 phosphorylation on the ARF-binding surface not resolved
   • Whether the same switch governs constitutive (non-granule) carriers untested
7. 2015 High

   Extended arfaptin-1 function to the retrograde pathway, demonstrating it negatively regulates Arl1-dependent endosome-to-Golgi transport via a required Arl1-binding interface.

   Evidence siRNA knockdown, WT/Arl1-binding-defective mutant rescue, Shiga toxin B retrograde assay, and affinity chromatography/MS

   PMID:25789876

   Open questions at the time

   • Mechanism linking Arl1 binding to retrograde rate control unclear
   • Interplay between anterograde scission and retrograde regulation not integrated
8. 2017 Medium

   Placed arfaptins within a lipid- and actin-driven carrier biogenesis pathway, showing BAR-domain recruitment guides clathrin/AP-1 carrier scission downstream of phosphoinositide conversion and F-actin tubulation.

   Evidence In vitro reconstitution, quantitative proteomics, lipidomics, and cell-based assays

   PMID:28854360

   Open questions at the time

   • Arfaptin-1-specific contribution not separated from arfaptin-2
   • Quantitative ordering of lipid, actin, and BAR steps not fully resolved

• How arfaptin-1's two GTPase interfaces (GTP-ARF inhibition versus Arl1/BAR-domain membrane shaping) are spatially and temporally coordinated at the TGN, and the structural basis of the PKD-phosphorylation switch, remain open.
• No structure of arfaptin-1 bound to ARF or Arl1 in the corpus
• Endogenous cargo selectivity of arfaptin-1 carriers undefined
• Non-secretory physiological roles uncharacterized